Ultra-late recurrence of non-small cell lung cancer over 10 years after curative resection.

ALK rearrangement lung cancer recurrence resection

Journal

Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700

Informations de publication

Date de publication:
2019
Historique:
received: 26 04 2019
accepted: 20 06 2019
entrez: 15 8 2019
pubmed: 15 8 2019
medline: 15 8 2019
Statut: epublish

Résumé

Most postoperative recurrences of non-small cell lung cancer (NSCLC) develop within 5 years after curative resection, with ultra-late recurrences developing over 10 years after the resection being rare. This study aimed to analyze the features of ultra-late recurrence in cases with NSCLC who had undergone curative resection. Among 1458 consecutive cases with NSCLC who underwent curative resection with systematic lymph node dissection during 1990-2006, 12 cases developed recurrence over 10 years after the resection. We defined the recurrence developing over 10 years after the resection as ultra-late recurrence and analyzed the factors related to it. Among the 1458 cases, recurrence developed in 476 (32.6%) cases. Of them, ultra-late recurrence developed in 12 (2.5%) cases. The ultra-late recurrence was histopathologically classified as adenocarcinoma in 11 cases and atypical carcinoid in 1 case. All cases were of invasive carcinoma. We compared ultra-late recurrence cases with non-recurrence cases and showed that none of the examined factors significantly influenced ultra-late recurrence; however, lymphatic invasion was close to significantly influencing it. There were two cases in which recurrence developed over 15 years after the resection; both cases were of adenocarcinoma with anaplastic lymphoma kinase (ALK) rearrangement. There is a possibility of ultra-late recurrence developing over 10 years after the resection of any invasive NSCLC. Lymphatic invasion is close to significantly influencing ultra-late recurrence. Furthermore, a long follow-up period may be required in cases with adenocarcinoma with ALK rearrangement because it has the possibility of recurrence over 15 years after the resection.

Identifiants

pubmed: 31410065
doi: 10.2147/CMAR.S213553
pii: 213553
pmc: PMC6648654
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6765-6774

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work.

Références

J Clin Oncol. 2002 Apr 15;20(8):1989-95
pubmed: 11956257
J Thorac Cardiovasc Surg. 2003 Aug;126(2):558-62
pubmed: 12928658
Ann Thorac Surg. 2004 Apr;77(4):1173-8
pubmed: 15063229
J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12
pubmed: 170482
J Thorac Oncol. 2007 Aug;2(8):686-93
pubmed: 17762334
Mod Pathol. 2009 Apr;22(4):508-15
pubmed: 19234440
J Clin Oncol. 2009 Sep 10;27(26):4247-53
pubmed: 19667264
Spine (Phila Pa 1976). 2010 Feb 1;35(3):E86-9
pubmed: 20075786
Chest. 2010 Jul;138(1):145-50
pubmed: 20382716
Lung Cancer. 2010 Sep;69(3):361-4
pubmed: 20659620
J Thorac Oncol. 2012 Apr;7(4):764-5
pubmed: 22425928
Ann Thorac Surg. 2012 Jun;93(6):1813-20; discussion 1820-1
pubmed: 22542070
Lung Cancer. 2013 Apr;80(1):99-101
pubmed: 23279872
J Clin Oncol. 2014 Sep 1;32(25):2780-7
pubmed: 25071109
Pathol Res Pract. 2014 Dec;210(12):1112-6
pubmed: 25238939
J Thorac Oncol. 2014 Nov;9(11):1618-24
pubmed: 25436796
Ann Thorac Surg. 2017 Feb;103(2):e119-e120
pubmed: 28109367
J Thorac Cardiovasc Surg. 1995 Jan;109(1):120-9
pubmed: 7815787
Eur J Cardiothorac Surg. 1997 Sep;12(3):380-4
pubmed: 9332915
J Thorac Cardiovasc Surg. 1999 Jan;117(1):32-6; discussion 37-8
pubmed: 9869756

Auteurs

Dai Sonoda (D)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Department of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Yosuke Matsuura (Y)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Junji Ichinose (J)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Masayuki Nakao (M)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Hironori Ninomiya (H)

Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Mingyon Mun (M)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Yuichi Ishikawa (Y)

Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Ken Nakagawa (K)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Yukitoshi Satoh (Y)

Department of Thoracic Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252-0374, Japan.

Sakae Okumura (S)

Department of Thoracic Surgical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.

Classifications MeSH